Characteristics of subjects in the three patient groups
| Cystic fibrosis | Healthy controls | Non-cystic fibrosis bronchiectasis | |
| Subjects n | 40 | 10 | 8 |
| Age years | 23±14 | 22±7 | 56±17 |
| Sex male/female | 19/21 | 4/6 | 5/3 |
| CRP mg·dL−1 | 0.8±0.5 | n.d. | 1.2±0.8 |
| WBC 109·L−1 | 11±7 | 7±4 | 10±6 |
| Total IgE kUI·L−1 | 49±34 | n.d. | 44±27 |
| FEV1 % pred | 66±15 | n.d. | 55±20 |
| MEF25 % pred | 39±27 | n.d. | 29±16 |
| Neutrophils in sputum % | 82±29 | 15±9 | 58±31 |
| Eosinophils in sputum % | 3±2.8 | 0.6±0.4 | 1.9±0.7 |
| Pseudomonas aeruginosa | 18 | n.d. | 2 |
| Aspergillus spp. | 22 | n.d. | 3 |
| IgE specific to Aspergillus fumigatus kU·L−1 | 2.3±1.6 | n.d. | 0.8±0.5 |
| IgG specific to A. fumigatus mg·L−1 | 59±35 | n.d. | 37±19 |
| A. fumigatus precipitins | 2/40 | n.d. | 0/3 |
| Candida spp. | 20 | n.d. | 2 |
| Aspergillus spp. and Candida spp. co-colonisation | 10 | n.d. | 0 |
| Staphylococcus aureus | 11 | n.d. | 0 |
| Haemophilus influenzae | 4 | n.d. | 0 |
| Achromobacter xylosoxidans | 5 | n.d. | 0 |
| Stenotrophomonas maltophilia | 6 | n.d. | 0 |
| Inhaled antibiotics | 18 | 0 | 2 |
| Inhaled corticosteroids | 16 | 0 | 2 |
| Dornase-α/DNase | 15 | 0 | 0 |
| Azithromycin | 11 | 0 | 1 |
| ΔF508 homozygous/heterozygous/other | 20/13/7 | n.d. | n.d. |
Data are presented as n or mean±sd, unless otherwise stated. CRP: C-reactive protein; WBC: white blood cells; FEV1: forced expiratory volume in 1 s; % pred: % predicted; MEF25: maximum expiratory flow at 25% of forced vital capacity; n.d.: not determined.